TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from NervGen Pharma ( (TSE:NGEN) ) is now available.
NervGen Pharma has successfully closed a US$10 million non-brokered private placement to support its anticipated Nasdaq listing and advance the development of its NVG-291 clinical program. The financing, which involved participation from institutional and accredited investors, including SCI Ventures and the Paul and Phyllis Fireman Charitable Foundation, will help NervGen strengthen its market position and potentially enhance shareholder value. The transaction also involved related party participation, requiring compliance with specific securities regulations.
The most recent analyst rating on (TSE:NGEN) stock is a Buy with a C$5.00 price target. To see the full list of analyst forecasts on NervGen Pharma stock, see the TSE:NGEN Stock Forecast page.
Spark’s Take on TSE:NGEN Stock
According to Spark, TipRanks’ AI Analyst, TSE:NGEN is a Neutral.
NervGen Pharma presents a high-risk, high-reward profile typical of early-stage biotech firms. Financial performance is weak due to ongoing R&D costs with no revenue, but technical indicators show positive momentum. Corporate events highlight potential upside from clinical advancements. However, the lack of earnings and reliance on financing remain significant concerns.
To see Spark’s full report on TSE:NGEN stock, click here.
More about NervGen Pharma
NervGen Pharma Corp. is a clinical-stage biopharmaceutical company focused on developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic disorders.
Average Trading Volume: 86,260
Technical Sentiment Signal: Buy
Current Market Cap: C$242.7M
Find detailed analytics on NGEN stock on TipRanks’ Stock Analysis page.